Is chrs a good buy

Coherus Biosciences (CHRS) is not a good buy at this time, based on the following analysis:

1. Financial Performance: CHRS reported a net loss of $12.92 million and a diluted EPS of -0.11, indicating that the company is currently unprofitable.
2. Revenue Growth: While the company had a significant revenue growth rate of 69.86%, this was primarily due to a one-time event, as the revenue fell 22% in total from three years ago. The recent revenue growth does not necessarily translate into future growth.
3. Stock Valuation Metrics: The company's P/E(TTM) is -1.36, suggesting that it is not currently profitable. The P/S ratio is 0.43, which is low and could indicate that the stock is undervalued. However, the P/B ratio is -1.44, indicating that the company has negative book value.
4. Technical Indicators: The stock's 5-day, 10-day, and 20-day moving averages are 1.03, 1.04, and 1.18, respectively. The RSI is -113.25%, which is extremely negative and suggests that the stock is oversold. The MACD and KDJ indicators are not provided, but the RSI indicates a strong sell signal.
5. Market Sentiment and Analyst Ratings: The stock has a "Moderate Buy" consensus rating with an average price target of $7.25, suggesting some analyst optimism. However, the stock's recent performance and financial metrics raise concerns.
6. Institutional Ownership and Short Interest: Institutional ownership is high at 65%, indicating significant influence by institutional investors. Short interest is at 21.87%, which is a bearish indicator.

In conclusion, Coherus Biosciences's current financial performance, lack of profitability, and negative P/B ratio suggest that it is not a good buy at this time. While there is potential for growth, the high level of institutional ownership and short interest indicate that investors are cautious about the company's prospects.